通过MRI对胰腺体积的纵向评估可预测进展至3期1型糖尿病
这项多中心前瞻性队列研究在65例多种糖尿病相关自身抗体阳性参与者中,比较MRI评估的胰腺体积、口服葡萄糖耐量试验(OGTT)衍生的代谢评分及两者联合对进展至3期1型糖尿病(T1D)的预测能力。结果显示胰腺体积指数(PVI)、Index60和DPTRS在进展者与未进展者间均有显著差异,PVI联合DPTRS的预测AUC最高(0.91)。
要点
- PVI、Index60和DPTRS在基线与进展至3期T1D显著相关(P < 0.005)。
- PVI与代谢检测指标在个体间不相关。
- PVI联合DPTRS预测进展的AUC为0.91,优于单一指标。
核心结论
- 胰腺体积和代谢指标反映进展至3期T1D的不同风险成分,两者联合可能提供优于任一单独指标的预测能力。
研究设计与样本
- 多中心前瞻性队列研究,纳入Type 1 Diabetes TrialNet Pathway to Prevention研究的65例多种自身抗体阳性参与者,进行胰腺MRI检查。
主要发现
- 在11例随后进展至3期T1D的个体与54例未进展者之间,基线PVI、Index60和DPTRS均存在显著差异(P < 0.005)。
- PVI在个体参与者中与代谢检测不相关。
- 在11例诊断为3期T1D的个体中,PVI纵向下降,而Index60和DPTRS升高。
- 基线测量预测进展至3期的受试者工作特征曲线下面积:PVI为0.76,Index60为0.79,DPTRS为0.79,PVI联合DPTRS为0.91。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multicenter prospective cohort study compared pancreas volume as assessed by MRI, metabolic scores derived from oral glucose tolerance testing (OGTT), and a combination of pancreas volume and metabolic scores for predicting progression to stage 3 type 1 diabetes (T1D) in individuals with multiple diabetes-related autoantibodies. RESEARCH DESIGN AND METHODS: Pancreas MRI was performed in 65 multiple autoantibody-positive participants enrolled in the Type 1 Diabetes TrialNet Pathway to Prevention study. Prediction of progression to stage 3 T1D was assessed using pancreas volume index (PVI), OGTT-derived Index60 score and Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), and a combination of PVI and DPTRS. RESULTS: PVI, Index60, and DPTRS were all significantly different at study entry in 11 individuals who subsequently experienced progression to stage 3 T1D compared with 54 participants who did not experience progression (P < 0.005). PVI did not correlate with metabolic testing across individual study participants. PVI declined longitudinally in the 11 individuals diagnosed with stage 3 T1D, whereas Index60 and DPTRS increased. The area under the receiver operating characteristic curve for predicting progression to stage 3 from measurements at study entry was 0.76 for PVI, 0.79 for Index60, 0.79 for DPTRS, and 0.91 for PVI plus DPTRS. CONCLUSIONS: These findings suggest that measures of pancreas volume and metabolism reflect distinct components of risk for developing stage 3 type 1 diabetes and that a combination of these measures may provide superior prediction than either alone.
引用
- Virostko J, Wright JJ, Williams JM, et al. Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes. Diabetes Care. 2024. PMID: 38151474. doi:10.2337/dc23-1681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。